Innovative Cell Therapies Angiocrine Bioscience specializes in proprietary engineered endothelial cell (E-CEL) therapies targeting serious hemato-oncologic and immunologic conditions, as well as tissue regeneration, representing significant market potential in regenerative medicine and personalized treatments.

Strong Clinical Pipeline With ongoing Phase 3 registration studies and recognition from the American Society of Hematology, the company demonstrates robust clinical progress, highlighting opportunities for collaborations, partnerships, and early adoption by healthcare providers.

Recent Funding & Grants Having secured a $6 million grant from CIRM and raising over $15 million in funding, Angiocrine is financially positioned for further R&D efforts, presenting opportunities for investors and strategic partners interested in biotech innovation.

Market Focus & Applications Targeting a wide range of applications including degenerative diseases, immune disorders, and ischemic conditions across multiple tissues, the company’s expansive pipeline offers multiple avenues for sales expansion into biotech, pharma, and specialty healthcare sectors.

Technology & Intellectual Property Utilizing cutting-edge genetic modification platforms and proprietary E-CEL technology, Angiocrine’s innovative approach creates pathways for licensing, joint ventures, or co-development deals with organizations seeking advanced regenerative solutions.